Computer-aided detection (CAD) and radiation therapy firm iCAD has opened a subsidiary in Paris to launch its deep-learning ProFound artificial intelligence (AI) platform in Europe.
The first use of the ProFound AI algorithm will be for digital breast tomosynthesis and the detection of breast cancer, according to the vendor. The AI process is designed to analyze each tomosynthesis section and provide markings of suspicious masses and microcalcifications in less than two minutes, after which ProFound AI assigns a score to each lesion to represent the certainty that the lesion is malignant. Radiologists can use the ratings as a guide to determine whether a lesion is suspicious and whether further action is required, the company said.
